Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Oramed Pharmaceuticals (Nasdaq: ORMP) announced that CEO Nadav Kidron will present an overview of the company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 3:00 p.m. ET, in New York. The presentation will highlight Oramed’s innovations in oral drug delivery systems, particularly its lead candidate, ORMD-0801, aimed at transforming diabetes treatment. The presentation will be accessible for 90 days via a provided link.

NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview and share the Company's latest updates at the H.C. Wainwright 24^th Annual Global Investment Conference, on September 13, 2022 in New York, NY.

 

 

Presentation Details:

H.C. Wainwright 24^th Annual Global Investment Conference 
Date: Tuesday, September 13, 2022 
Time: 3:00 p.m. E.T. 
Location: Lotte New York Palace, New York, NY

The presentation will be viewable starting Tuesday, September 13, 2022, at 3:00 p.m. Eastern time, and will be available for 90 days, through the following link: https://journey.ct.events/view/fbd3fb46-d695-4516-9e06-8d9247a157ab.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).

For more information, please visit www.oramed.com.

Logo - https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg

Company contact: 
Zach Herschfus 
+1-844-9-ORAMED
zach@oramed.com

View original content:https://www.prnewswire.com/news-releases/oramed-to-present-at-hc-wainwright-24th-annual-global-investment-conference-301618100.html

SOURCE Oramed Pharmaceuticals Inc.

FAQ

What date will Oramed present at the H.C. Wainwright 24th Annual Global Investment Conference?

Oramed will present on September 13, 2022.

What time is Oramed's presentation at the H.C. Wainwright Conference?

The presentation is scheduled for 3:00 p.m. Eastern time.

Where is the H.C. Wainwright Conference being held?

The conference will take place at Lotte New York Palace, New York, NY.

How can I view Oramed's presentation?

The presentation will be available for viewing through a link starting September 13, 2022, for 90 days.

What is ORMD-0801 by Oramed?

ORMD-0801 is Oramed's lead candidate for an oral insulin capsule aimed at treating diabetes.